<DOC>
	<DOCNO>NCT01741038</DOCNO>
	<brief_summary>This personalized anti-cancer vaccine protocol include in-situ ( body ) cancer vaccine step combine kill single metastatic tumor lesion use cryoablation order cause release tumor-specific marker immune system inject bioengineered allogeneic immune cell ( AlloStim ) lesion adjuvant order modulate immune response educate immune system kill tumor cell ever reside body .</brief_summary>
	<brief_title>AlloStim® In-Situ Vaccine Pre-Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Colorectal cancer ( CRC ) rank third common cancer worldwide . Metastasis main reason death CRC patient . The current drug use treat colorectal cancer provide important treatment option patient , limitation include drug resistance , poor efficacy severe side effect . Development new therapeutic strategy KRAS mutant well BRAF mutant tumor therefore highly need order offer new category drug ( immunotherapy ) . This study target population mCRC patient progress two line chemotherapy eligible targeted therapy due mutation KRAS BRAF . This Phase II/III , randomize , open-label , multicenter , control , two arm study design determine efficacy term OS safety InSituVax ( AlloStim+ Cryoablation ) personalize in-situ anti-cancer vaccine protocol ( Treatment Arm ) compare Physician 's Choice ( PC ) Treatment + Cryoablation ( Control Arm ) Metastatic Colorectal Cancer . Subjects randomize 2:1 treatment control arm .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Adult male female subject age 18 year old screen visit 2 . Pathological diagnosis colorectal adenocarcinoma 3 . Metastatic disease least one lesion liver Primary intact resect Metastatic lesion ( ) liver nonresectable Extrahepatic disease acceptable 4 . KRAS/BRAF mutant disease KRAS wild type w/previous antiEGFR treatment 5 . At least one liver lesion able visualize ultrasound determine safely assessable percutaneous cryoablation 6 . Previous treatment failure 2 previous line active systemic chemotherapy metastatic disease : Previous chemotherapy must include one line oxaliplatin ( e.g . FOLFOX ) previous second line irinotecan ( e.g . FOLFIRI ) without bevacizumab If KRAS wild type , least one antiEGFR therapy first second line Treatment failure due disease progression toxicity Disease progression 2nd line therapy must document radiologically occur within 30 day follow last administration 2nd line chemotherapy 7 . ECOG performance score : 01 8 . Adequate hematological function : Absolute granulocyte count ≥ 1,200/mm3 , Platelet count ≥ 100,000/mm3 , PT/INR ≤ 1.5 correctable &lt; 1.5 time interventional procedure , Hemoglobin ≥ 9 g/dL ( may correct transfusion ) 9 . Adequate Organ Function : Creatinine ≤ 1.5 mg/dL , Total bilirubin ≤ 1.5 time ULN , Alkaline phosphatase ≤ 2.5 time ULN , AST SGOT ≤ 2.5 time ULN , ALT SGPT≤2.5 time ULN 10 . EKG without clinically relevant abnormality 11 . Female subject : Not pregnant lactate 12 . Subjects child bear potential must agree use adequate contraception 13 . Study specific inform consent native language subject 1 . Peritoneal carcinomatosis 2 . Moderate severe ascites require medical intervention 3 . Prior hepatectomy , ablation chemoembolization liver lesion 4 . Prior pelvic radiotherapy 5 . Clinical radiological evidence brain metastasis/leptomeningeal involvement 6 . Symptomatic asthma COPD lung condition require treatment steroid 7 . Pulmonary lymphangitis symptomatic pleural effusion ( grade ≥ 2 ) result pulmonary dysfunction require active treatment oxygen saturation &lt; 92 % room air 8 . Bevacizumab ( Avastin® ) treatment within 6 week schedule cryoablation 9 . No Regorafenib prior Study Period 10 . Anticoagulant medication concomitant medical condition ( unless safely discontinue invasive cryoablation , biopsy intratumoral injection procedure ) 11 . Prior allogeneic bone marrow/stem cell solid organ transplant 12 . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 5 mg/day prednisone ) within 30 day 1st day study treatment Topical corticosteroid permit 13 . Prior diagnosis active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) . Well control Type I diabetes allow . 14 . Prior experimental therapy 15 . History blood transfusion reaction 16 . Known allergy bovine product 17 . Progressive viral bacterial infection All infection must resolve patient must remain afebrile seven day without antibiotic prior place study 18 . Cardiac disease symptomatic nature 19 . History HIV positivity AIDS 20 . Concurrent medication know interfere platelet function coagulation ( e.g. , aspirin , ibuprofen , clopidogrel , warfarin ) unless medication discontinue appropriate time period base drug halflife know activity ( e.g. , aspirin 7 day ) prior cryoablation procedure 21 . History severe hypersensitivity monoclonal antibody drug contraindication study drug 22 . Psychiatric addictive disorder condition , opinion investigator , would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer Vaccine</keyword>
	<keyword>AlloStim®</keyword>
	<keyword>Immunovative</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Allogeneic Cell Therapy</keyword>
	<keyword>Cryoablation</keyword>
</DOC>